By Fineline Cube 
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) released its Q1 2025 financial report, recording RMB 9.42 billion (USD 1.3 billion) in revenues, RMB 765 million (USD 105 million) in net profits, and RMB 1.056 billion (USD 145.2 million) in operating cash flow.
Regulatory and Pipeline Milestones
During the quarter, Fosun Pharma achieved significant regulatory milestones, with one in-house developed drug approved in China and one in-licensed product approved in the European Union (EU). Additionally, the company advanced multiple investigational new pipelines targeting lung cancer and breast cancer into pivotal clinical and regulatory stages.-Fineline Info & Tech